Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma
NCT05816863 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 32
Last updated 2023-04-18
Summary
Our study is aim to evaluate the efficacy and safety of pabolizumab in neoadjuvant immunotherapy of locally advanced microsatellite-unstable gastric adenocarcinoma.
Conditions
- Gastric Cancer
- Gastric Adenocarcinoma
Interventions
- DRUG
-
pabolizumab
pabolizumab IV every 3 weeks (q3w)
Sponsors & Collaborators
-
Peking University Cancer Hospital & Institute
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-01
- Primary Completion
- 2024-03-01
- Completion
- 2024-03-01
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
NCT01015339 ·Status: UNKNOWN ·Phase: PHASE3
-
Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer
NCT02163291 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma
NCT03631615 ·Status: UNKNOWN ·Phase: PHASE2
-
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
NCT05385809 ·Status: UNKNOWN
-
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
NCT04675866 ·Status: UNKNOWN ·Phase: NA
-
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer
NCT05385900 ·Status: UNKNOWN ·Phase: NA
-
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
NCT02494583 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
NCT06235164 ·Status: ACTIVE_NOT_RECRUITING
-
PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma
NCT04341857 ·Status: UNKNOWN ·Phase: PHASE2
-
AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
NCT04556253 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer
NCT02229058 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
NCT04443036 ·Status: UNKNOWN ·Phase: NA
-
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
NCT05041153 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
NCT05216237 ·Status: UNKNOWN ·Phase: PHASE2
-
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
NCT01585987 ·Status: COMPLETED ·Phase: PHASE2
-
Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer
NCT05982301 ·Status: RECRUITING ·Phase: PHASE2
-
Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
NCT03801668 ·Status: UNKNOWN ·Phase: PHASE3
-
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
NCT05149807 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
NCT06580574 ·Status: RECRUITING ·Phase: PHASE2
-
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
NCT03675737 ·Status: COMPLETED ·Phase: PHASE3
-
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
NCT06956716 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
First Line Chemotherapy for Advanced Cancer
NCT01980810 ·Status: TERMINATED ·Phase: PHASE2
-
Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
NCT05593458 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06415669 ·Status: RECRUITING ·Phase: PHASE2